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Introduction
Skeletogenesis occurs through two mechanisms: intramembra-
nous ossifi  cation and endochondral ossifi  cation (Karsenty and 
Wagner, 2002). During intramembranous ossifi  cation, which 
occurs in some cranial bones and the clavicle, mesenchymal 
cells differentiate directly into osteoblasts without a chondro-
cyte intermediary step. In endochondral bone formation, mes-
enchymal cells fi  rst condense to shape the future skeletal 
elements. The mesenchymal cells within these condensations 
differentiate into chondrocytes, which express α1(II) collagen, 
whereas the α1(I) collagen–expressing undifferentiated mesen-
chymal cells at the periphery of the condensations form the 
perichondrium. After the formation of the cartilaginous tem-
plates, chondrocytes further differentiate into prehypertrophic 
chondrocytes and then into hypertrophic chondrocytes, which 
express α1(X) collagen. Terminally differentiated hypertrophic 
chondrocytes also express matrix metalloproteinase 13 (Mmp13; 
also called collagenase 3). This hypertrophic chondrocyte dif-
ferentiation step does not occur in skeletal elements that are 
destined to be permanent cartilage. Finally, the osteoblasts in 
the perichondrium invade the hypertrophic chondrocyte area 
and deposit bone matrix.
Skeletogenesis is tightly controlled by transcription fac-
tors. Among them, Runx2, a transcription factor containing a 
runt DNA binding domain, is a key gene for osteoblast differen-
tiation (Ducy et al., 1997). In addition, Runx2 plays multiple 
and opposite roles during chondrogenesis (Takeda et al., 2001; 
Komori, 2002; Hinoi et al., 2006). On one hand, Runx2 is tran-
siently expressed in prehypertrophic chondrocytes, where it, in 
conjunction with Runx3 for some skeletal elements, is neces-
sary to initiate chondrocyte hypertrophy (Yoshida et al., 2004), 
the ultimate event of chondrogenesis. Accordingly, Runx2 con-
stitutive expression in nonhypertrophic chondrocytes leads to 
premature and ectopic chondrocyte hypertrophy and, thereby, 
bone formation (Takeda et al., 2001). On the other hand, through 
its perichondrial expression, Runx2 prevents chondrocyte mat-
uration (Hinoi et al., 2006). To date, histone deacetylase 4 
(HDAC4) is the only protein known to regulate Runx2 function 
during chondrogenesis (Vega et al., 2004). This contrasts sharply 
with the larger number of molecules regulating Runx2 function 
during osteogenesis (Bialek et al., 2004; Kronenberg, 2004; 
Komori, 2006) and suggests that additional regulators of Runx2’s 
ability to favor chondrocyte hypertrophy may exist.
Filamins are a family of large cytoplasmic actin binding 
proteins that cross-link fi  lamentous actin into a three-dimen-
sional network (Stossel et al., 2001). The family consists of three 
members in mammals, Filamin A, B, and C (Flna, Flnb, and 
Flnc). All three members share well-conserved actin binding 
domains and a rodlike domain of 24 repeats, which is interrupted 
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by two poorly conserved hinge domains (Popowicz et al., 2006). 
All three members are widely expressed, although Flnc is more 
restricted to skeletal and cardiac muscle (Feng and Walsh, 2004). 
Studies in different model organisms indicate that Filamins may 
interact with >30 proteins, thus implicating them in many cellu-
lar functions ranging from mechanical stability, to cell–cell and 
cell–matrix interactions, to integrators of signal transductions 
(Stossel et al., 2001; van der Flier and Sonnenberg, 2001; Popowicz 
et al., 2006).
Genetic evidence indicates that Filamins are essential for 
the development of multiple organs in human, including skele-
ton (Robertson et al., 2003; Krakow et al., 2004). For instance, 
mutations in Flnb are found in fi  ve human skeletal disorders: 
spondylocarpotarsal synostosis syndrome (SSS), Boomerang 
dysplasia, atelosteogenesis I, atelosteogenesis III, and Larsen 
syndrome (Krakow et al., 2004). The recessive SSS, character-
ized by short stature and fusions of vertebral, carpal, and tarsal 
bones, is caused by stop codon mutations within rod domain re-
peats, whereas the other dominant disorders are associated with 
missense mutations or small in-frame deletions. Patients with 
Boomerang dysplasia (Bicknell et al., 2005) have underossifi  ca-
tion of the limb bones and vertebrae. Atelosteogenesis I and III 
(Farrington-Rock et al., 2006) patients have vertebral ab normalities, 
disharmonious skeletal maturation, hypoplastic long bones, and 
joint dislocations. Patients with Larsen syndrome (Zhang et al., 
2006) have multiple joint dislocations, craniofacial abnormali-
ties, and accessory carpal bones. The molecular mechanisms 
whereby mutations in Flnb result in skeletal abnormalities 
remain unknown.
To study how Flnb mutations could lead to skeletal dis-
orders, we generated mice defi  cient in full-length Flnb protein 
and found that the mutant mice display a phenotype similar to 
the recessive SSS. Cellular and histological analysis showed 
that these defects are due to premature and/or ectopic chondro-
cyte hypertrophy in skeletal elements that should be permanent 
cartilage. Molecular studies showed that these abnormalities are 
due to an increase in Runx2 activity. Here, we also show that 
Flnb does not interact with either Runx2 or HDAC4 but can 
bind to Smad3, a protein expressed in prehypertrophic chondro-
cytes and able to interact with Runx2 (Sakou et al., 1999; Kang 
et al., 2005). These results demonstrate for the fi  rst time that 
Flnb can infl  uence the function of a transcription factor, identify 
a new mechanism whereby Runx2’s function during chondro-
genesis is regulated, and provide a molecular basis for SSS.
Results
Flnb mutant mice display ectopic 
mineralization
The Flnb gene trap embryonic stem (ES) cell line contains a 
β-galactosidase neomycin insertion within the 20th intron of Flnb 
(Fig. 1 A; see Materials and methods). The 20th exon of Flnb 
splices into the insertion to generate a fusion transcript, but it does 
not produce any wild-type transcript (Fig. 1 C and Fig. S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200703113/DC1). 
The mutant transcript is predicted to encode a truncated Flnb 
protein of 1,624 of the full-length 2,602 amino acids and to 
be fused with β-galactosidase (Fig. 1 D). Intercrosses of Flnb 
Figure 1.  Generation of Flnb mutant mice. 
(A) The gene trap ES cell line contains a β-geo 
insertion within the 20th intron of Flnb gene. 
BglII, which has a single restriction site within 
the insertion, was used to digest genomic DNA 
for genotyping. The exact locations of the 
primers used for genotyping and RT-PCRs are 
indicated by the arrows. (B) Southern blotting 
detects a mutant band of 3.1 kb and a wild 
type of 3.5 kb. (C) RT-PCR analysis shows no 
full-length Flnb gene expression in the homozy-
gous mutants. The rtf1/rtr primer pair ampliﬁ  es 
the wild-type Flnb transcript spanning the β-geo 
insertion. The rtf2/galr primer pair ampli  ﬁ  es 
the fusion transcript of the Flnb and β-geo 
insertion. Total RNA from the liver and kidney 
of each genotyped mouse was used as the 
template. (D) A Flnb–β-galactosidase fusion 
protein is present in the mutant mice at P0 as 
shown by LacZ staining. (E) The surviving ho-
mozygous mutant mouse is smaller compared 
with a wild-type littermate and has severe ky-
phosis (arrow), indicated by x-ray analysis at 
P30. (F) Flnb mutants die postnatally. At P5 
and P21, fewer than the expected numbers 
of homozygotes are observed. At E18.5, the 
numbers of each genotype are consistent with 
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heterozygotes in the 129/Ola-C57BL/6 mixed genetic back-
ground generate homozygous Flnb mice at Mendelian ratios at 
embryonic day (E) 18.5 (Fig. 1 F). However, at postnatal day (P) 5 
or P21, the number of homozygous mutants is 50 and 90% 
decreased, respectively. The few surviving homozygous mutants 
are runted and have abnormal postures, with x-ray analysis show-
ing severe kyphosis (Fig. 1 E). All these features are reminiscent 
of the clinical manifestation of SSS (Krakow et al., 2004).
Staining of skeletal preparations with Alizarin red for min-
eralized ECM and Alcian blue for unmineralized cartilaginous 
ECM reveals multiple skeletal defects in the Flnb mutants. For 
instance, similar to what is seen in SSS patients, homozygous 
mice have both cervical vertebrae and carpal bone fusions. In-
deed, although in wild-type P30 mice, unmineralized cartilagi-
nous ECM separates the seven cervical vertebrae, the intervertebral 
ECM of the mutant mice was stained by Alizarin red, indicating 
that this ECM was mineralized, causing vertebral fusions (Fig. 
2 A). In P0 mutant mice, mineralization of the cartilage ECM, 
although detectable, is less extensive, suggesting that the fusion of 
cervical vertebrae develops progressively. The mineralization of 
intervertebral ECM was fi  rst detectable at E17.5, whereas no dif-
ference in cervical vertebrae staining was seen between wild type 
and mutant at E16.5, suggesting that the cartilage develops prop-
erly in the homozygous mutants but becomes mineralized (Fig. 
2 A). In addition, the cartilage that would normally separate carpal 
bones in the wild-type mice is ectopically mineralized in the mu-
tant mice. At P0, blue staining cartilaginous ECM separates the 
carpal bones, whereas by P15, this ECM is becoming mineral-
ized, leading to fusions of carpal bones (Fig. 2 B).
Homozygous Flnb mutant mice also display abnormal 
 ossifi  cation in the chondrocostal cartilage of the rib cage and 
sterna. In wild-type mice at all stages examined, chondrocostal 
cartilage and cartilage separating the sternebrae never ossify 
and are stained by Alcian blue. In contrast, in homozygous mu-
tant mice, although the chondrocostal cartilage is stained with 
Alcian blue at P0, it stains progressively with Alizarin red at 
P15 and P30, indicating that this ECM is becoming prematurely 
mineralized (Fig. 3 A). Similarly, cartilaginous areas between 
sternebrae become mineralized in the mutant mice. Collectively, 
these ectopic ECM mineralization processes observed in cervi-
cal, carpal, and rib cage suggest that one of the Flnb functions is 
to regulate chondrocyte differentiation.
Ectopic mineralization in Flnb mutant 
mice is due to ectopic chondrocyte 
differentiation
To determine if this ectopic mineralization was caused by ecto-
pic chondrocyte hypertrophy, we analyzed the expression of 
molecular markers of proliferating, prehypertrophic, and hyper-
trophic chondrocytes in ribs by in situ hybridization. We used 
probes to α1(II) collagen, a gene expressed in proliferating and 
prehypertrophic chondrocytes; Indian hedgehog (Ihh) and par-
athyroid hormone–related peptide receptor (Ppr), two pre-
hypertrophic chondrocyte markers; α1(X) collagen, a marker 
of hypertrophic chondrocytes; Mmp13, a terminally differentiated 
hypertrophic marker; and α1(I) collagen, which is expressed in 
osteoblasts and mesenchymal cells in the bone collar. At P0, 
although α1(II) collagen is expressed in the cartilage area be-
tween sternebrae 3/4 of wild-type mice, its expression cannot be 
detected in mutant mice (Fig. 3 B). Instead, the Flnb
mut cells 
express α1(X) collagen and Mmp13 (Fig. 3 C), indicating that 
the chondrocytes have differentiated into hypertrophic chondro-
cytes. Similarly, α1(II) collagen is expressed in the cartilagi-
nous area between sternebrae 2/3 of P0 in wild-type mice, but 
its expression at this location is diminished in mutant mice. 
Instead, these cells express Ihh, Ppr, and α1(X) collagen. These 
results indicate that the chondrocytes within that area are 
un  dergoing hypertrophy in the homozygous mutant mice at P0 
Figure 2.  Skeletal defects in Flnb mutant mice similar to human spondylo-
carpotarsal syndrome. (A) Ectopic ECM mineralization in the cervical ver-
tebrae of the Flnb mutants. In wild-type mice, seven cervical vertebrae are 
separated by blue staining cartilaginous ECM at all stages. In the P30 and 
P0 homozygous mutants, the cervical vertebrae are fused (arrows) with the 
absence of blue staining cartilage in between. The cervical fusion pheno-
type appears at E17.5, as the blue staining cartilage between cervical ver-
tebrae 2 and 3 is replaced by red staining mineralized ECM. No fusions 
are visible at E16.5 in the homozygous mutants. (B) Ectopic ECM mineral-
ization in the carpal bones of the Flnb mutants. In wild-type mice, bones 
are separated by blue staining cartilaginous ECM (arrows). In the P30 and 
P15 mutants, carpal bones are fused with little or no blue staining cartilage 
in between. At P0, the cartilage appears to be normal in mutant mice.JCB • VOLUME 178 • NUMBER 1 • 2007  124
(Fig. 3 C). At P5, α1(II) collagen is no longer expressed in the 
cartilage area between sternebrae 2/3 and 3/4, but osteoblasts are 
present, as demonstrated by the expression of α1(I) collagen (Fig. 
3 B). This observation explains the presence of ectopic bone 
formation in the sterna.
At P0, cells of both wild-type and Flnb
mut chondrocostal 
cartilage express α1(II) collagen but not α1(X) collagen, indi-
cating that chondrocytes in the chondrocostal cartilage are not 
hypertrophic (Fig. 3 B). However, 5 d later, α1(X) collagen ex-
pression can be detected in the chondrocostal cartilage of the 
homozygous mutant mice, suggesting that hypertrophic chon-
drocyte differentiation has occurred (Figs. 3, B and D). Collec-
tively, these results reveal that there is uncontrolled differentiation 
of chondrocytes into hypertrophic chondrocytes in the Flnb
mut 
chondrocostal cartilage, a cellular abnormality reminiscent of 
what was seen in mice overexpressing Runx2 in chondrocytes 
(α1[II]-Runx2 transgenic mice; Takeda et al., 2001).
Figure 3.  Ectopic ECM mineralization is caused by abnormal chondrocyte 
differentiation in the Flnb mutants. (A) Ectopic ECM mineralization in ribs. 
In wild-type mice, the four sternebrae are separated by blue staining carti-
lage and the chondrocostal cartilage remains blue at all stages. In homo-
zygous mutant mice, sternebrae 3 and 4 are already fused without blue 
staining cartilage in between. The cartilage between sternebrae 2 and 3 is 
undergoing mineralization at P0 and completely mineralized with red 
staining by P15. The chondrocostal cartilage of the mutant mice is stained 
blue at P0 and partly stained red at P15 and P30. (B) In situ hybridizations 
with collagen markers. At P0, in wild-type ribs, chondrocytes between ster-
nebrae 2 and 3, as well as those between sternebrae 3 and 4, express 
α1(II) collagen. In mutant ribs, chondrocytes between sternebrae 3 and 4 
do not express α1(II) collagen and have already become mineralized. 
Meanwhile, chondrocytes between sternebrae 2 and 3 are expressing 
α1(X) collagen in the middle and are undergoing hypertrophy. At P5, in 
the wild-type rib, the chondrocytes between sternebrae 2 and 3, as well as 
those between sternebrae 3 and 4, still express α1(II) collagen. In addition, 
chondrocytes within the chondrocostal cartilage do not express α1(X) 
collagen. However, in mutant ribs, α1(X) collagen can be readily detected 
within the chondrocostal chondrocytes. Furthermore, chondrocytes be-
tween sternebrae 2 and 3 do not express α1(II) collagen and instead are 
now completely mineralized. At both P0 and P5, no difference is seen in 
the α1(I) collagen–expressing bone collar between the wild-type and mu-
tant mice. The arrows point to the cartilage between sternebrae 3/4, and 
arrowheads point to the chondrocostal cartilage. (C) Ectopic chondrocyte 
hypertrophy in the cartilage between sternebrae at P0. In wild-type ribs, 
chondrocytes separate the sternebrae 2/3 and 3/4. In mutant ribs, chon-
drocytes are becoming hypertrophic between sternebrae 2/3, as indicated 
by the expression of Ihh, Ppr, and α1(X) collagen in the mutants. The area 
between sternebrae 3/4 is becoming mineralized, as indicated by the ex-
pression of Mmp13. The arrows point to the cells between sternebrae 2/3 
and the arrowhead points to the cells between sternebrae 3/4. (D) Magni-
ﬁ  ed cellular phenotype in the chondrocostal cartilage at P5. The chondro-
cytes in the middle of the cartilage are enlarged and expressing α1(X) 
collagen prematurely in the mutants. α1(I) collagen is an osteoblast marker, 
α1(II) collagen is a proliferating and prehypertrophic chondrocyte marker, 
α1(X) collagen is a hypertrophic chondrocyte marker, Ihh is a prehypertro-
phic chondrocyte marker, Ppr is a prehypertrophic chondrocyte marker, 
and Mmp13 is a terminally differentiated hypertrophic marker. The arrows 
point to hypertrophic chondrocytes.
Figure 4.  Genetic interaction between Runx2 and Flnb. (A and B) Skeletal 
preparations of cervical vertebrae and rib cage, respectively, at P0. The 
rectangular bars illustrate the mineralized (red) and the unmineralized (blue) 
ECM in cervical vertebrae. In wild-type mice, seven cervical vertebrae and 
four sternebrae are separated by blue staining cartilage. In Flnb
mut mice, the 
cervical vertebrae are extensively fused and the cartilage is ectopically min-
eralized. In Runx2
+/−; Flnb
mut mice, the cervical vertebrae are separated by 
blue staining ECM. The blue staining cartilage between sternebrae 2/3 is 
also restored, although the cartilage between sternebrae 3/4 is still missing. 
The arrowheads point to intervertebral discs between sternebrae 2/3. (C) In 
situ hybridization analysis of α1(II) and α1(X) collagen expression in ribs. In 
wild-type and Runx2
+/−; Flnb
mut mice, sternebrae 2/3 is separated by α1(II) 
collagen–expressing chondrocytes. However, in Flnb
mut mice, α1(X) colla-
gen but no α1(II) collagen is expressed in the area between sternebrae 2/3. 
The skeletal elements were stained with alcian blue and alizarin red. The 
arrows refer to the cartilage between sternebrae 2/3. (D) Statistics on the 
rescue experiment. The cervical vertebrae fusion phenotype is completely 
rescued after removing one copy of Runx2; the same is true for the fusion 
between sternebrae 2 and 3. The fusion between sternebrae 3 and 4 is not 
rescued. F, fusion of bone elements; N, normal bone elements.FILAMIN B REGULATES CHONDROCYTE HYPERTROPHY • ZHENG ET AL. 125
Genetic interaction between Flnb and Runx2
The similarity between Flnb mutant and α1(II)-Runx2 pheno-
types suggests that Flnb and Runx2 may interact genetically, with 
Flnb acting as a negative regulator of Runx2 activity. To test this 
hypothesis, we generated Flnb mutant mice on a Runx2 haplo-
insuffi  ciency background and examined them for ectopic mineral-
ization. Remarkably, Runx2
+/−; Flnb
mut mice have completely 
normal cervical vertebrae (Fig. 4 A), and the sterna phenotype 
observed in Flnb
mut mice is partially rescued (Fig. 4 B). Accord-
ingly, normal expression of α1(II) and α1(X) was restored in 
Runx2
+/−; Flnb
mut mice (Fig. 4 C). The rescue, complete or partial, 
is always fully penetrant (Fig. 4 D). These results provide genetic 
evidence that Flnb and Runx2 interact and suggest that Flnb 
regulates chondrocyte hypertrophy by inhibiting Runx2 activity.
Flnb inhibits Runx2 by regulating Smad3 
phosphorylation
How does a cytoplasmic molecule like Flnb inhibit the function 
of a nuclear transcription factor like Runx2? We were unable to 
detect mislocalization of Runx2 and HDAC4 proteins in the Flnb 
mutants or to identify biochemical interactions between Flnb 
and Runx2 or HDAC4 (Fig. 5, A and B; and Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200703113/DC1). 
Although negative and therefore to be interpreted cautiously, these 
observations suggest that Flnb must interact with another protein.
Filamin A, another member of the Filamin protein family, 
has been shown to bind CBFβ, a nuclear factor that can interact 
with Runx proteins. Through this interaction, Filamin A prevents 
CBFβ from entering the nucleus to activate the Runx1 transcrip-
tion factor (Yoshida et al., 2005). Therefore, we examined 
whether Flnb also binds CBFβ. We failed, however, to detect 
any interaction between Flnb and CBFβ (Fig. 5 C), nor could we 
see abnormal intracellular localization of CBFβ in chondrocytes 
(Fig. S2). Thus, the Runx2 interaction with Flnb appears to be 
CBFβ independent under the conditions of these assays.
Deletion of a phosphorylation site on Smad3 causes ecto-
pic chondrocyte hypertrophy, suggesting that TGF-β–Smad3 
signals repress chondrocyte differentiation (Ferguson et al., 
2000; Yang et al., 2001). Because phosphorylated Smad3 has 
been shown to recruit HDAC4 to inhibit Runx2 activity in osteo-
blasts by forming a HDAC4–Smad3–Runx2 complex (Kang 
et al., 2005), we tested whether Flnb could repress Runx2 activity 
by interacting with Smad3. Indeed, three lines of evidence sup-
port the notion that a direct interaction between Flnb and Smad3 
exists. First, Smad3 can be immunoprecipitated with Flnb in an 
in vitro overexpression assay (Fig. 5 D). Notably, compared with 
Smad3, Smad2 and -5 show no detectable interaction with Flnb 
(Fig. 5, E and F), although an interaction with Smad4 and -6 is 
also detected (Fig. S2). Second, endogenous Smad3 protein can 
be immunoprecipitated by tagged Flnb protein (Fig. 5 G). Third, 
Flnb directly interacts with Smad3 in a pull-down assay (Fig. 5, 
H and I). Because the phosphorylation of Smad3 is important in 
chondrocyte differentiation, we further examined the amount of 
active Smad3 in mutant versus wild type. The amount of phos-
phorylated Smad3 is signifi  cantly increased in the rib chondro-
cytes of Flnb mutants by Western blot analysis (Fig. 5 J), although 
this could not be readily detected by immunostaining (Fig. S2). 
Meanwhile, the total amount of Smad3 is not changed in the 
mutants (Fig. 5 K). Thus, Flnb may regulate Smad3 to ensure the 
accumulation of an appropriate amount of activated Smad3 in 
the nucleus (Fig. 6 A). An excessive amount of phosphorylated 
Smad3 may titrate out HDAC4, leading to a failure to form the 
repressive HDAC4–Smad3–Runx2 complex. In this model, 
amounts of HDAC4 need not to be changed (Fig. S2). In support 
of this model, we noticed that Filb
mut rib chondrocytes contain 
more p-Smad3–HDAC4 complex than in wild-type cells because 
more HDAC4 can be coimmunoprecipitated by anti–p-Smad3 
antibody (Fig. 5 L). The titration of HDAC4 proposed in this 
model may disrupt the repressive HDAC4–Smad3–Runx2 com-
plex, resulting in the improper activation of Runx2 (Fig. 6 B).
Discussion
Together, our data show that disruption of Flnb leads to ab-
normal differentiation of chondrocytes into hypertrophic chondro-
cytes, causing ectopic bone formation in cartilaginous elements 
Figure  5.  Smad3 is a mediator between Filamin B and Runx2. (A–F) Immuno-
precipitation shows that the C terminus of Filamin B interacts with Smad3. 
Anti-myc antibody can pull down Smad3 (D), but not Runx2 (A), HDAC4 
(B), CBFβ (C), Smad2 (E), or Smad5 (F) in the cotransfection protein extract 
(compare lanes 4 with lanes 2). Filamin B is tagged with myc, whereas 
Runx2, HDAC4, CBFβ, Smad2, Smad3, and Smad5 are tagged with ﬂ  ag. 
Lanes 1 and 2 are loading controls. Lanes 3 and 4 are immunoprecipita-
tions with anti-myc antibody. Lo, loading; F, ﬂ  ag. (G) Recombinant myc-
tagged Flnb protein immunoprecipitates endogenous Smad3 protein in 
293T cells. (H) Coomassie staining shows recombinant GST, GST-tagged 
Flnb, and His-tagged Smad3 proteins derived from bacteria. (I) In vitro pull-
down assay shows that GST-tagged Flnb directly interacts with his-tagged 
Smad3, whereas GST alone does not. (J) Western blot shows that there are 
more phosphorylated Smad3 proteins in Flnb mutants than in the wild-type 
cells. (K) The total amount of Smad3 protein is not changed in the mutants 
compared with wild-type cells. (L) Coimmunoprecipitation shows that more 
HDAC4 protein can be pulled down with anti–p-Smad3 antibody in Flnb 
mutant chondrocytes, suggesting that there are more p-Smad3–HDAC4 
complexes in the Flnb mutants than in the wild type. Tubulin serves as the 
loading controls for the immunoprecipitations or immunoblottings.JCB • VOLUME 178 • NUMBER 1 • 2007  126
of the cervical vertebrae, carpal bone, and rib cage. That this 
phenotype can be rescued by inactivating one Runx2 allele iden-
tifi  es an Flnb/Runx2 genetic cascade regulating chondrogenesis. 
Thus, the regulation of Runx2 function during chondrogenesis 
is more complicated than previously thought.
Our data indicate that the action of Flnb on Runx2 is me-
diated through the TGF-β–Smad3 pathway, likely by control-
ling phosphorylated Smad3. Interestingly, similar to the effect 
of the accumulation of phosphorylated Smad3, loss of TGF-β–
Smad3 signals also causes excessive chondrocyte hypertrophy 
(Yang et al., 2001). These seemingly contradictory results led us 
to propose that the homeostasis of activated Smad3 protein is 
essential for suppressing Runx2 activity because the readout of 
TGF-β depends on the amount of HDAC4–Smad3–Runx2 
triple protein complex in the nucleus (Fig. 6). Consequently, 
either excessive Smad3 or lack of Smad3 will result in Runx2 
activation. This is consistent with both the role of Smad3 in pre-
venting chondrocyte differentiation (Ferguson et al., 2000; Yang 
et al., 2001; Tchetina et al., 2006) and with reports suggesting 
that TGF-β can up-regulate Mmp13 production in human os-
teoarthritic chondrocytes (Tardif et al., 1999; Moldovan et al., 
2000). We remain aware that further experiments are needed to 
test all aspects of this model. These results do not exclude the 
possibility that other mechanisms also contribute to the pheno-
type observed in the mutant mice.
The interaction between Flnb and Smad3 in chondrocyte 
differentiation revealed in this study indicates that Filamins are 
involved in TGF-β–Smad signaling. Supporting this notion, 
Filamin A physically interacts with Smad2 and -5 and function-
ally promotes Smad2 phosphorylation, which is suggested by 
the lack of phosphorylation in Filamin A–defective human mel-
anoma cells (Sasaki et al., 2001). Although our results indicate 
that Flnb normally prevents excessive Smad3 phosphorylation, 
we hypothesize that the action of Filamins on Smad proteins 
may vary in different cell types.
From a biomedical point of view, this study provides a mouse 
model for SSS, a disease associated with nonsense mutations 
in FLNB; more important, it uncovers a molecular mechanism 
explaining the vertebral and carpal bone fusions seen in these 
patients. In contrast to the ectopic ossifi  cation caused by non-
sense mutations in FLNB, missense mutations in FLNB cause 
the absence or underossifi  cation of limb bones and vertebrae in 
Boomerang dysplasia (Bicknell et al., 2005) and atelosteogen-
esis I and III (Krakow et al., 2004). In these dominant disorders, 
we speculate that the mutant Flnb causes delayed chondrocyte 
hypertrophy or affects osteoblast differentiation. In fact, Flnb 
may also regulate Runx2 function in osteoblast differentiation, as 
indicated by the less developed occipital bone, which is formed 
through intramembranous ossifi   cation, in Runx2
+/−; Flnb
mut 
than in Runx2
+/−; Flnb
wt mice (Fig. S3, available at http://www
.jcb.org/cgi/content/full/jcb.200703113/DC1). Examining more 
alleles of Flnb in the mouse will provide further insights into its 
additional roles in skeletal development. In summary, our study 
not only reveals a new mechanism for regulating chondrocyte 
differentiation but also provides a molecular basis for the skel-
etal dysplasia caused by FLNB nonsense mutations.
Materials and methods
Generation of mice and lines used
The Filamin B gene trap mice were generated with the 129/Ola ES cell line 
XD076 from BayGenomics (http://baygenomics.ucsf.edu/). The ES cell line 
was expanded and injected into C57BL/6-Albino blastocysts in the Darwin 
Transgenic Mouse Core facility at Baylor College of Medicine (http://imgen
.bcm.tmc.edu/dtmc/). Chimeras were bred to C57BL/6 mice, and germline 
transmission was achieved. Mice were genotyped using Southern blotting 
after BglII digestion with a probe to the 5′ end of the β-geo insertion, which is 
ampliﬁ  ed with the primer pair: ﬁ  lb-5southF (A  A  C  A  T  G  G  C  T  T  G  C  T  G  T  G  A  C  T  G  ) 
and ﬁ  lb-5southR  (G  G  A  G  A  G  G  G  A  A  A  T  C  C  G  A  A  G  T  C  ). The Runx2 knockout 
was used previously (Takeda et al., 2001). The primers for genotyping the 
Runx2 mice are as follows: Cbfa1DB (C  A  C  G  G  A  G  C  A  C  A  G  G  A  A  G  T  T  G  G  G  ), 
Cbfa1DF (T  G  A  G  C  G  A  C  G  T  G  A  G  C  C  C  G  G  T  G  G  ), and Neo3F (A  A  G  A  T  G  G  A  T-
T  G  C  A  C  G  C  A  G  G  T  T  C  T  C  ). The Cbfa1DB/Neo3F primer pair ampliﬁ  es  the 
mutant allele, whereas the Cbfa1DB/Cbfa1DF primer pair ampliﬁ  es  the 
wild-type allele. For timed matings, the morning of the vaginal plug was des-
ignated E0.5. All animal protocols were approved by the Institutional Animal 
Care and Use Committee of Baylor College of Medicine.
RT-PCR analysis
Total RNA was prepared from liver or kidney dissected from P21 Flnb 
homozygous, heterozygous, and wild-type mice (n = 3 for each genotype) 
using RNAqueous-4PCR kit (Ambion). Transcripts were ampliﬁ  ed using Su-
perscript One-Step RT-PCR Systems (Invitrogen). The primers to amplify the 
wild-type Flnb transcript spanning the β-geo insertion are as follows: rtf1 
(T  C  T  T  C  C  C  A  C  A  T  A  C  G  A  T  G  C  A  A  ) and rtr (T  C  C  A  C  T  A  C  A  A  A  G  C  C  C  A  C  C  T  C  ). 
The primers to amplify the mutant transcript (fusion of Flnb and β-geo inser-
tion) are as follows: rtf2 (C  C  T  A  T  A  T  C  C  C  T  G  A  T  A  A  G  A  C  C  G  G  A  C  G  C  ) and gal 
(G  A  C  A  G  T  A  T  C  G  G  C  C  T  C  A  G  G  A  A  G  A  T  C  G  ).
Skeletal preparation
Mice were dissected, ﬁ   xed in 95% ethanol overnight, and stained in 
0.015% alcian blue (Sigma-Aldrich) dye overnight. The carcasses were 
treated with 2% KOH for 1 to several days until most soft tissue disappeared. 
After removing the remaining soft tissues carefully with forceps, the mice 
were stained in 0.005% alizarin red (Sigma-Aldrich) solution for 30 min to 
several hours depending on the age of the mice. Finally, skeletons were 
cleared in a 20% glycerol/1% KOH solution. At least four mice of each 
genotype were analyzed for each stage.
𝗃-Galactosidase assay
Mice at P0 were dissected so that most tissues other than skeleton are 
  removed. The skeletons were ﬁ  xed in 0.2% glutaraldehyde for 1 h at RT fol-
lowed by washing in PBS twice. Fixed specimens were then put in fresh 
staining solution overnight at RT. The staining solution was made by mixing 
1 ml 10× stock solution, 250 μl 0.2 M EGTA, and 250 μl 40 mg/ml X-gal 
Figure 6.  A model of how Filamin B regulates chondrocyte hypertrophy. 
(A) In a normal cell, the C terminus of Filamin B recruits Smad3 and pre-
vents it from being phosphorylated. However, the unsequestrated Smad3 
undergoes phosphorylation, enters the nucleus, and interacts with both 
Runx2 and HDAC4 to form a protein complex. As a result, HDAC4 re-
presses Runx2 activity and inhibits the abnormal differentiation of chondro-
cytes into hypertrophic chondrocytes. (B) In Flnb mutants, the Filamin B 
protein lacking the C terminus cannot bind Smad3 so that possibly more 
Smad3 proteins are phosphorylated and enter the nucleus. In the nucleus, 
some of the phosphorylated Smad3 bind HDAC4, whereas others remain 
isolated. The isolated Smad3 proteins compete for Runx2 binding sites with 
the Smad3–HDAC4 complex. Thus, fewer Smad3–HDAC4 complexes bind 
Runx2, leading to Runx2 hyperactivity and thereby the abnormal differenti-
ation of chondrocytes into hypertrophic chondrocytes. P, phosphorylation.FILAMIN B REGULATES CHONDROCYTE HYPERTROPHY • ZHENG ET AL. 127
into 8.5 ml PBS. The 10× stock solution was made as follows: for 100 ml 
solution, add 1.646 g K4Fe(CN)6 Ferro, 2.112 g K3Fe(CN)6 Ferri, 2 ml 
1 M MgCl2, 2 ml 1% NP40, and 0.01 g sodium deoxycholate. X-gal stock 
solution was made by dissolving 100 mg X-gal in 2.5 ml dimethylfor-
mamide. All microscopy for skeletal preparation and X-gal staining of the 
skeleton are performed with Stemi SV11 microscopy (Carl Zeiss Micro-
Imaging, Inc.) with 0.5× (Plan) and 1.0× (Planapo) objectives at RT. 
Pictures were taken with a color video camera (DXC 300 3CCD; Sony), 
captured through the Spot software (Diagnostic Instruments), and further 
processed with Photoshop (Adobe).
Histology and in situ hybridization
Tissues were ﬁ  xed in 4% paraformaldehyde/PBS overnight at 4°C. Mice 
  obtained after P0 were decalciﬁ  ed in TBD-2 solution (Thermo Shandon) over-
night at 4°C. Specimens were dehydrated and embedded in parafﬁ  n and 
sectioned at 5 μm. For histological analysis, sections were stained with he-
matoxylin and eosin. In situ hybridization was performed using digoxigenin-
labeled riboprobes (Roche). The α1(I), α1(II), and α1(X) probes were used 
previously (Takeda et al., 2001). Hybridizations were performed overnight 
at 60°C, and washes were performed at 65°C. Sections were then incubated 
for 2 h with alkaline phosphatase–linked anti-digoxigenin antibody (1:2,000; 
Roche) at RT followed by color reactions with BM purple substrate (Roche). 
Sections were ﬁ  nally counterstained with nuclear fast red (Vector Laborato-
ries) and mounted with Permount. Three mice of each genotype were ana-
lyzed for each stage. The microscopy for all histology and in situ sections 
were performed using a microscope (AxioPlan2; Carl Zeiss MicroImaging, 
Inc.) with 5× (Plan-Neoﬂ  uar), 10× (Plan-Apochromat), or 20× (Plan-
Apochromat) objectives at RT. All images were taken with AxioCam (Carl Zeiss 
MicroImaging, Inc.), captured through the AxioVision software (Carl Zeiss 
MicroImaging, Inc.), and processed with Photoshop software (Adobe).
Plasmid construction
Smad-expressing mammalian plasmids were provided by K. Watanabe 
(National Institute for Longevity Sciences, Aichi, Japan; pF:Smad1, -2, -4, -5, 
and -6) and R. Derynck (University of California, San Francisco, San Francisco, 
CA; ﬂ  ag-Smad3; Sasaki et al., 2001; Kang et al., 2005). The CBFβ-
expressing plasmid was obtained from T. Watanabe (Tohoku University, 
Sendai, Japan; Yoshida et al., 2005). To generate myc-tagged N terminus–
truncated mammalian-expressing Filamin B, the C-terminal 231-amino-acid 
coding region was generated by PCR and inserted into the StuI–XbaI sites 
of the CS2+MT vector. To produce his-tagged Smad3 protein, PCR-ampliﬁ  ed 
Smad3 gene was subcloned into NdeI and BamHI sites of a bacterial 
expression vector, pET-15b (Novagen). To produce GST fusion protein, the 
C terminus of Filamin B was PCR ampliﬁ  ed and subcloned into NdeI and 
HindIII sites of a pGEX2TL.
Recombinant protein puriﬁ  cation
BL21-pLysS was transformed with His-tagged Smad3 and GST-fused Fila-
min B bacterial expression vectors, respectively. After induction with IPTG, 
the bacterial pellets were lysed by sonication in the presence of Ni-column 
binding buffer (20 mM TrisCl, pH 7.9, 500 mM NaCl, and 5 mM Imidazole) 
and GST binding buffer (20 mM TrisCl, pH 7.9, 1 M NaCl, 0.2 mM EDTA, 
2 mM DTT, and 10% Glycerol), respectively, and centrifugation was followed. 
From each supernatant, His-tagged Smad3 and GST-fused Filamin B proteins 
were isolated by Ni-NTA (GE Healthcare) chromatography and glutathione-
coupled Sepharose (GE Healthcare) chromatography.
GST pull-down assays
5 mg of puriﬁ  ed His-tagged Smad3 protein was incubated with either 10 mg 
immobilized GST or GST-fused Filamin B on glutathione-coupled Sepharose 
in BC300 (20 mM Tris, pH 7.9, 0.2 mM EDTA, 300 mM KCl, 20% glycerol, 
0.1% NP-40, and 1 mM PMSF) solution containing 2 mg/ml BSA for 6 h at 
4°C. The immobilized GST or GST-fused Filamin B beads were washed 
extensively with BC300 and analyzed by immunoblot after SDS-PAGE.
Immunoprecipitation and immunoblotting
For the immunoprecipitation and immunoblotting for the interaction be-
tween overexpressed Filamin B and overexpressed Smad3, 293T cells 
were cotransfected with myc-tagged Flnb and ﬂ  ag-tagged Runx2, HDAC4, 
CBFβ, and Smad proteins, respectively, using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s manual. 48 h later, cells were har-
vested and washed once with cold PBS. The cell pellet was suspended and 
lysed by adding 10 times the volume of hypotonic buffer. The hypotonic 
buffer is composed of 50 mM Tris-Cl, pH 7.5, 2 mM EDTA, 0.1% NP-40, 
1 mM PMSF, and phosphatase inhibitors. The lysates were subjected to 
immunoprecipitation with anti-myc antibody (Santa Cruz Biotechnology, Inc.) 
and protein A agarose overnight, followed by Western blotting with anti-
myc and anti-Flag (Sigma-Aldrich) antibodies.
For the immunoprecipitation and immunoblotting for the interaction 
between overexpressed Filamin B and endogenous Smad3, 293T cells 
transfected with myc-tagged Filamin B expression vector using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s manual. 48 h 
later, cells were harvested and washed once with PBS. The cell pellet was 
lysed by adding 10 times more hypotonic buffer than the pellet volume and 
resuspending the pellet. The hypotonic buffer is composed of 50 mM Tris-
Cl, pH 7.5, 2 mM EDTA, 0.1% NP-40, 1 mM PMSF, and phosphatase in-
hibitors. The lysates were subjected to immunoprecipitation with anti-myc 
antibody and protein A agarose for overnight, followed by Western blot-
ting with anti-myc and -Smad3 (Upstate Biotechnology) antibodies.
For the detection of p-Smad3 level and coimmunoprecipitation of 
p-Smad3 and HDAC4, cartilaginous tissues from Rib cages of wild-type and 
Filamin B mutant mice at P4 were homogenized in 500 ml lysis buffer using 
a tissue miser (Tekmar). The lysis buffer is composed of 50 mM Tris, pH 7.5, 
2 mM EDTA, 150 mM NaCl, 1% Triton X-100, and protease and phospha-
tase inhibitor cocktail. These lysates were subjected to immunoprecipitation 
with anti–phospho-Smad2/3 antibody (Santa Cruz Biotechnology, Inc.) and 
protein A agarose for 6 h, followed by immunoblotting with anti-Smad3 
and anti-HDAC4 (Santa Cruz Biotechnology, Inc.) antibody. As an input 
control of the immunoprecipitation, the lysates were subjected to immuno-
blotting with anti-tubulin antibody (Santa Cruz Biotechnology, Inc.).
Online supplemental material
Fig. S1 shows the expression of different portions of the Filamin B transcript 
in the mutant compared with the wild type. Fig. S2 shows the expression of 
CBFβ, HDAC4, p-Smad3, and Runx2 in the chondrocytes and interaction 
between Filamin B and Smad4 or -6. Fig. S3 shows the aggravated occipi-
tal bone phenotype by deleting Filamin B in the background of Runx2 hap-
loinsufﬁ  ciency. Online supplemental material is available at http://www
.jcb.org/cgi/content/full/jcb.200703113/DC1.
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